AMO Pharma Secures FDA, MHRA, and Health Canada Alignment on Registrational Trial Design for AMO-02 in Congenital Myotonic Dystrophy Type 1
核心洞察
AMO Pharma (搜索) reached agreement with the FDA, MHRA, and Health Canada on the design of a registrational study for AMO-02 (oral tideglusib) in congenital myotonic dystrophy type 1 (搜索) (cDM1).
The trial will use hospitalization as the primary efficacy endpoint, reflecting the significant burden of this life-threatening rare neuromuscular disorder.
Multiple functional assessments will serve as secondary outcome measures to characterize disease progression and capture the variable clinical features of cDM1.
AMO Pharma (搜索) Limited, a privately held clinical-stage specialty biopharmaceutical company, today announced alignment with regulatory agencies in the United States, United Kingdom, and Canada on the design of a registrational clinical study for its investigational therapy AMO-02 (oral tideglusib) in the treatment of congenital myotonic dystrophy type 1 (搜索) (cDM1).
The design requirements and primary outcome choice for the registrational study are based on advice provided to AMO Pharma (搜索) by the U.S. Food and Drug Administration (FDA), the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), and Health Canada following meetings conducted over the last six months. AMO-02 is an investigational compound that has not been approved by any regulatory authority, and its safety and efficacy have not been established to date.
Hospitalization as the Primary Endpoint
Based on the regulatory advice received, the registrational study for AMO-02 is expected to use hospitalization as the primary efficacy endpoint. Hospitalization represents a significant burden for people living with cDM1 and their caregivers, as cDM1 is a potentially life-threatening disorder associated with multiple medical co-morbidities. The clinical study will also include a range of functional assessments as secondary outcome measures to help characterize disease progression and capture key features of cDM1, which can vary widely in its clinical presentation.
AMO Pharma (搜索) also plans to engage the cDM1 community through a survey to better understand the impact of symptoms and hospitalizations associated with this disorder.
"We appreciate the thoughtful engagement of FDA, MHRA and Health Canada throughout this important process and are pleased to have received feedback that informs the design of the planned registrational study for AMO-02," said Dr. Mike Snape, chief executive officer at AMO Pharma (搜索). "With insights from these regulatory agencies, we are now well positioned to plan and execute a registrational study as quickly as possible. For individuals and families affected by cDM1, the need for new treatment options remains critical, and we look forward to updating on our progress in advancing this program in the months ahead."
Disease Background and Unmet Need
Congenital DM1 is a rare, inherited neuromuscular disorder that can cause serious and lifelong challenges affecting muscle function, learning difficulties, development, cardiac problems, and overall health. Many affected individuals experience serious complications requiring hospitalization and ongoing multidisciplinary care. There are currently limited treatment options available for individuals living with the condition.
"Families affected by cDM1 carry an extraordinary burden, often managing serious health challenges from the earliest days of life," said Lisa Harvey-Duren, a leading patient advocate in DM1 and a consultant for AMO Pharma (搜索). "Alignment on a trial design that reflects clinically meaningful outcomes is an important methodological step in evaluating potential therapies for cDM1. The selection of patient-relevant outcome measures is an important consideration in clinical research design for congenital myotonic dystrophy."
Regulatory and Clinical Context
The scientific advice received by AMO Pharma (搜索) from regulators is consistent with language regarding cDM1 adopted in the FY27 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations bill.
"Having participated in the REACHCDM-X study of AMO-02 over the last four years, I welcome this advice from regulators in Canada, the U.S. and the U.K., as the field looks to plan future interventional studies in cDM1, which is a serious and underserved condition," said Professor Hanns Lochmuller, principal investigator in the REACH-CDM study at the Children's Hospital of Eastern Ontario, in Ottawa, Canada.
The company expects to provide an update on the planned initiation of the study during the third quarter of 2026. AMO Pharma (搜索) noted that the scientific advice provided by regulators is not legally binding with regards to any future application for the product concerned and cannot be taken as indicative of any future agreed position. In addition to developing AMO-02 for DM1, the company is also progressing AMO-02 as a clinical-stage treatment for Arrhythmogenic Right Ventricular Cardiomyopathy (搜索) (ARVC).